Phase 2
N=90
Analgesic Efficacy of Inter Pleural Ropivacaine Road in Post Thoracotomy Pain for Oncologic Surgery
Postoperative Pain · Cancer
Bottom Line
View on ClinicalTrials.gov: NCT00210132 ↗Enrolled (actual)
90
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: Proportion of Patients With Major Post-operative Pain at Mobilization Following Lung Surgery by Posterolateral Thoracotomy — 4; 3 Participants — p=0.99
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Ropivacaine (Drug); Reference (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Institut Bergonié
- Primary completion
- Jun 2006
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Proportion of Patients With Major Post-operative Pain at Mobilization Following Lung Surgery by Posterolateral Thoracotomy |
4; 3 | 0.99 |
| SECONDARY Post-operative Morphine Consumption Following Lung Surgery by Posterolateral Thoracotomy |
29.9; 15.6 | 0.69 |
Summary
Thoracic surgery via posterolateral thoracotomy causes significant postoperative pain.
There are several methods of postoperative pain relief, including intravenous analgesics and local-regional analgesia techniques. Although thoracic epidural remains the gold standard, it is not without complications, which are rare but serious, and should be reserved for trained teams or patients with high morbidity.
Intrapleural analgesia is a simple method, performed by the surgeon intraoperatively.
Its effectiveness is controversial and the results remain inconsistent. Ropivacaine is a recently marketed local anesthetic with a modest vasoconstrictive effect. The variation in plasma levels of ropivacaine obtained by this technique has not yet been evaluated.
The purposes of this study are:
1. To determine the efficacy of inter pleural analgesia
2. To determine the plasmatic concentration of ropivacaine by inter pleural road
Eligibility Criteria
Inclusion Criteria
- Thoracotomy for oncology thoracic surgery
- Secondary or primary cancer
- American Society of Anesthesiology (ASA) class 1 or 2
Exclusion Criteria
- Ropivacaine hypersensibility
- Psychiatric disorders
- Incapacity of using visual analog scale
Data sourced from ClinicalTrials.gov (NCT00210132). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.